156 related articles for article (PubMed ID: 26804704)
1. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Manton CA; Johnson B; Singh M; Bailey CP; Bouchier-Hayes L; Chandra J
Sci Rep; 2016 Jan; 6():18953. PubMed ID: 26804704
[TBL] [Abstract][Full Text] [Related]
2. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for the treatment of glioblastoma.
Roth P; Mason WP; Richardson PG; Weller M
Expert Opin Investig Drugs; 2020 Oct; 29(10):1133-1141. PubMed ID: 32746640
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
[TBL] [Abstract][Full Text] [Related]
6. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
[TBL] [Abstract][Full Text] [Related]
7. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.
Bullova P; Cougnoux A; Marzouca G; Kopacek J; Pacak K
Endocrinology; 2017 Oct; 158(10):3097-3108. PubMed ID: 28938421
[TBL] [Abstract][Full Text] [Related]
9. Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.
Gozdz A
Curr Oncol; 2023 Nov; 30(11):9676-9688. PubMed ID: 37999122
[TBL] [Abstract][Full Text] [Related]
10. The Relative Efficacy of Available Proteasome Inhibitors in Preventing Muscle Contractures Following Neonatal Brachial Plexus Injury.
Das I; Shay-Winkler K; Emmert ME; Goh Q; Cornwall R
J Bone Joint Surg Am; 2024 Apr; 106(8):727-734. PubMed ID: 38194588
[TBL] [Abstract][Full Text] [Related]
11. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Miller CP; Ban K; Dujka ME; McConkey DJ; Munsell M; Palladino M; Chandra J
Blood; 2007 Jul; 110(1):267-77. PubMed ID: 17356134
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
[TBL] [Abstract][Full Text] [Related]
13. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
15. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
Morin A; Soane C; Pierce A; Sanford B; Jones KL; Crespo M; Zahedi S; Vibhakar R; Mulcahy Levy JM
Neurooncol Adv; 2020; 2(1):vdaa051. PubMed ID: 32642704
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
19. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Gras Navarro A; Espedal H; Joseph JV; Trachsel-Moncho L; Bahador M; Gjertsen BT; Kristoffersen EK; Simonsen A; Miletic H; Enger PØ; Rahman MA; Chekenya M
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31319548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
